Literature DB >> 29912295

Relationships Between Tau and Glucose Metabolism Reflect Alzheimer's Disease Pathology in Cognitively Normal Older Adults.

Jenna N Adams1, Samuel N Lockhart1, Lexin Li2, William J Jagust1,3.   

Abstract

Tau is associated with hypometabolism in patients with Alzheimer's disease. In normal aging, the association between tau and glucose metabolism is not fully characterized. We used [18F] AV-1451, [18F] Fluorodeoxyglucose, and [11C] Pittsburgh Compound-B (PiB) PET to measure associations between tau and glucose metabolism in cognitively normal older adults (N = 49). Participants were divided into amyloid-negative (PiB-, n = 28) and amyloid-positive (PiB+, n = 21) groups to determine effects of amyloid-β. We assessed both local and across-brain regional tau-glucose metabolism associations separately in PiB-/PiB+ groups using correlation matrices and sparse canonical correlations. Relationships between tau and glucose metabolism differed by amyloid status, and were primarily spatially distinct. In PiB- subjects, tau was associated with broad regions of increased glucose metabolism. In PiB+ subjects, medial temporal lobe tau was associated with widespread hypometabolism, while tau outside of the medial temporal lobe was associated with decreased and increased glucose metabolism. We further found that regions with earlier tau spread were associated with stronger negative correlations with glucose metabolism. Our findings indicate that in normal aging, low levels of tau are associated with a phase of increased metabolism, while high levels of tau in the presence of amyloid-β are associated with hypometabolism at downstream sites.
© The Author(s) 2018. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Alzheimer’s disease; aging; amyloid-β; glucose metabolism; tau

Mesh:

Substances:

Year:  2019        PMID: 29912295      PMCID: PMC6458898          DOI: 10.1093/cercor/bhy078

Source DB:  PubMed          Journal:  Cereb Cortex        ISSN: 1047-3211            Impact factor:   5.357


  53 in total

1.  Graphical analysis of PET data applied to reversible and irreversible tracers.

Authors:  J Logan
Journal:  Nucl Med Biol       Date:  2000-10       Impact factor: 2.408

Review 2.  Synaptic energy use and supply.

Authors:  Julia J Harris; Renaud Jolivet; David Attwell
Journal:  Neuron       Date:  2012-09-06       Impact factor: 17.173

3.  In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum.

Authors:  Hanna Cho; Jae Yong Choi; Mi Song Hwang; You Jin Kim; Hye Mi Lee; Hye Sun Lee; Jae Hoon Lee; Young Hoon Ryu; Myung Sik Lee; Chul Hyoung Lyoo
Journal:  Ann Neurol       Date:  2016-07-08       Impact factor: 10.422

4.  Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.

Authors:  Willemijn J Jansen; Rik Ossenkoppele; Betty M Tijms; Anne M Fagan; Oskar Hansson; William E Klunk; Wiesje M van der Flier; Victor L Villemagne; Giovanni B Frisoni; Adam S Fleisher; Alberto Lleó; Mark A Mintun; Anders Wallin; Sebastiaan Engelborghs; Duk L Na; Gäel Chételat; José Luis Molinuevo; Susan M Landau; Niklas Mattsson; Johannes Kornhuber; Osama Sabri; Christopher C Rowe; Lucilla Parnetti; Julius Popp; Tormod Fladby; William J Jagust; Pauline Aalten; Dong Young Lee; Rik Vandenberghe; Catarina Resende de Oliveira; Elisabeth Kapaki; Lutz Froelich; Adrian Ivanoiu; Tomasz Gabryelewicz; Marcel M Verbeek; Páscual Sanchez-Juan; Helmut Hildebrandt; Vincent Camus; Marzena Zboch; David J Brooks; Alexander Drzezga; Juha O Rinne; Andrew Newberg; Alexandre de Mendonça; Marie Sarazin; Gil D Rabinovici; Karine Madsen; Milica G Kramberger; Agneta Nordberg; Vincent Mok; Barbara Mroczko; David A Wolk; Philipp T Meyer; Magda Tsolaki; Philip Scheltens; Frans R J Verhey; Pieter Jelle Visser; Dag Aarsland; Daniel Alcolea; Myriam Alexander; Ina S Almdahl; Steven E Arnold; Inês Baldeiras; Henryk Barthel; Bart N M van Berckel; Kaj Blennow; Mark A van Buchem; Enrica Cavedo; Kewei Chen; Elena Chipi; Ann D Cohen; Stefan Förster; Juan Fortea; Kristian S Frederiksen; Yvonne Freund-Levi; Olymbia Gkatzima; Mark Forrest Gordon; Timo Grimmer; Harald Hampel; Lucrezia Hausner; Sabine Hellwig; Sanna-Kaisa Herukka; Peter Johannsen; Aleksandra Klimkowicz-Mrowiec; Sebastian Köhler; Norman Koglin; Koen van Laere; Mony de Leon; Viviana Lisetti; Wolfgang Maier; Jan Marcusson; Olga Meulenbroek; Hanne M Møllergård; John C Morris; Arto Nordlund; Gerald P Novak; George P Paraskevas; Gayan Perera; Oliver Peters; Inez H G B Ramakers; Lorena Rami; Eloy Rodríguez-Rodríguez; Catherine M Roe; Uros Rot; Eckart Rüther; Isabel Santana; Johannes Schröder; Sang W Seo; Hilkka Soininen; Luiza Spiru; Erik Stomrud; Hanne Struyfs; Charlotte E Teunissen; Stephanie J B Vos; Linda J C van Waalwijk van Doorn; Gunhild Waldemar; Åsa K Wallin; Jens Wiltfang; Henrik Zetterberg
Journal:  JAMA Psychiatry       Date:  2018-01-01       Impact factor: 21.596

5.  Cognition, glucose metabolism and amyloid burden in Alzheimer's disease.

Authors:  Ansgar J Furst; Gil D Rabinovici; Ara H Rostomian; Tyler Steed; Adi Alkalay; Caroline Racine; Bruce L Miller; William J Jagust
Journal:  Neurobiol Aging       Date:  2010-04-24       Impact factor: 4.673

6.  Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden.

Authors:  Gil D Rabinovici; Ansgar J Furst; Adi Alkalay; Caroline A Racine; James P O'Neil; Mustafa Janabi; Suzanne L Baker; Neha Agarwal; Stephen J Bonasera; Elizabeth C Mormino; Michael W Weiner; Maria L Gorno-Tempini; Howard J Rosen; Bruce L Miller; William J Jagust
Journal:  Brain       Date:  2010-01-15       Impact factor: 13.501

7.  Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging.

Authors:  Anne Maass; Samuel N Lockhart; Theresa M Harrison; Rachel K Bell; Taylor Mellinger; Kaitlin Swinnerton; Suzanne L Baker; Gil D Rabinovici; William J Jagust
Journal:  J Neurosci       Date:  2017-11-30       Impact factor: 6.167

8.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents.

Authors:  Chester A Mathis; Yanming Wang; Daniel P Holt; Guo-Feng Huang; Manik L Debnath; William E Klunk
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

9.  Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease.

Authors:  Gérard N Bischof; Frank Jessen; Klaus Fliessbach; Julian Dronse; Jochen Hammes; Bernd Neumaier; Oezguer Onur; Gereon R Fink; Juraj Kukolja; Alexander Drzezga; Thilo van Eimeren
Journal:  Ann Clin Transl Neurol       Date:  2016-10-20       Impact factor: 4.511

10.  Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.

Authors:  Yi Li; Juha O Rinne; Lisa Mosconi; Elizabeth Pirraglia; Henry Rusinek; Susan DeSanti; Nina Kemppainen; Kjell Någren; Byeong-Chae Kim; Wai Tsui; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236

View more
  27 in total

Review 1.  Imaging the evolution and pathophysiology of Alzheimer disease.

Authors:  William Jagust
Journal:  Nat Rev Neurosci       Date:  2018-11       Impact factor: 34.870

2.  Sleep as a Potential Biomarker of Tau and β-Amyloid Burden in the Human Brain.

Authors:  Joseph R Winer; Bryce A Mander; Randolph F Helfrich; Anne Maass; Theresa M Harrison; Suzanne L Baker; Robert T Knight; William J Jagust; Matthew P Walker
Journal:  J Neurosci       Date:  2019-06-17       Impact factor: 6.167

3.  Level of education mitigates the impact of tau pathology on neuronal function.

Authors:  Merle C Hoenig; Gérard N Bischof; Özgür A Onur; Juraj Kukolja; Frank Jessen; Klaus Fliessbach; Bernd Neumaier; Gereon R Fink; Elke Kalbe; Alexander Drzezga; Thilo van Eimeren
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-10       Impact factor: 9.236

4.  Regional multimodal relationships between tau, hypometabolism, atrophy, and fractional anisotropy in atypical Alzheimer's disease.

Authors:  Irene Sintini; Christopher G Schwarz; Peter R Martin; Jonathan Graff-Radford; Mary M Machulda; Matthew L Senjem; Robert I Reid; Anthony J Spychalla; Daniel A Drubach; Val J Lowe; Clifford R Jack; Keith A Josephs; Jennifer L Whitwell
Journal:  Hum Brain Mapp       Date:  2018-12-13       Impact factor: 5.038

5.  Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment.

Authors:  Jiehui Jiang; Can Sheng; Guanqun Chen; Chunhua Liu; Shichen Jin; Lanlan Li; Xueyan Jiang; Ying Han
Journal:  Geroscience       Date:  2022-05-18       Impact factor: 7.713

6.  Relationships among tau burden, atrophy, age, and naming in the aphasic variant of Alzheimer's disease.

Authors:  Adam Martersteck; Jaiashre Sridhar; Christina Coventry; Sandra Weintraub; M-Marsel Mesulam; Emily Rogalski
Journal:  Alzheimers Dement       Date:  2021-09-08       Impact factor: 21.566

7.  Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer's disease: A tracer kinetic modeling study.

Authors:  Ming-Kai Chen; Adam P Mecca; Mika Naganawa; Jean-Dominique Gallezot; Takuya Toyonaga; Jayanta Mondal; Sjoerd J Finnema; Shu-Fei Lin; Ryan S O'Dell; Julia W McDonald; Hannah R Michalak; Brent Vander Wyk; Nabeel B Nabulsi; Yiyun Huang; Amy Ft Arnsten; Christopher H van Dyck; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2021-03-24       Impact factor: 6.200

8.  Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.

Authors:  Amelia Strom; Leonardo Iaccarino; Lauren Edwards; Orit H Lesman-Segev; David N Soleimani-Meigooni; Julie Pham; Suzanne L Baker; Susan M Landau; William J Jagust; Bruce L Miller; Howard J Rosen; Maria Luisa Gorno-Tempini; Gil D Rabinovici; Renaud La Joie
Journal:  Brain       Date:  2022-04-18       Impact factor: 15.255

Review 9.  The human connectome in Alzheimer disease - relationship to biomarkers and genetics.

Authors:  Meichen Yu; Olaf Sporns; Andrew J Saykin
Journal:  Nat Rev Neurol       Date:  2021-07-20       Impact factor: 44.711

Review 10.  Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future?

Authors:  Donald E Moss
Journal:  Int J Mol Sci       Date:  2020-05-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.